Drug intelligence / Profile preview

hymenialdisine

Development stage: Preclinical
Modality: Small Molecules

Overview

Hymenialdisine is a marine sponge-derived pyrroloazepine alkaloid with pan kinase inhibitory activity. It acts as a natural inhibitor of multiple protein kinases, including those involved in NF-kB and MAPK signaling pathways, and has demonstrated anticancer, anti-inflammatory, and bone-protective effects. In preclinical studies, hymenialdisine suppresses osteoclastogenesis while promoting osteoblast differentiation, suggesting potential applications in osteoporosis treatment. It is not approved for any clinical use.[4][5][7]

Other names: 10Z-Hymenialdisine(Z)-Hymenialdisine82005-12-7 (CAS)95569-43-0 (CAS)Z-HYMENIALDISINE[2][3][6]

Targets

GSK3 (Glycogen synthase kinase 3 beta)CDK2 (Cyclin-dependent kinase 2)CSNK1G3 (Casein kinase 1 gamma 3)

Beyond the preview

Go deeper on hymenialdisine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hymenialdisine.

Explore the full profile